Drug Prices
The AHA restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule.
AHA, others express support of the 340B federal drug pricing program and strongly encourage Congress to protect the program as they consider broader changes to our nation’s health care system.
A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The report recommends the pursuit of legislation that would enable price negotiation in Medicare Parts B and D, with those negotiated prices also…
It is imperative that Congress invest in America’s hospitals and health systems to ensure
that the nation’s health care needs can be met today and into the future. The AHA supports
investments in infrastructure, such as the health care workforce, behavioral health, the
accessibility and…
The American Hospital Association (AHA) would like to share hospital and health system priorities that would benefit patients and communities around the country that we would like to see included in the upcoming budget reconciliation legislation.
President Biden urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each year.
President Biden today signed an executive order (EO) establishing a “whole-of-government” effort to promote competition in the American economy. The EO includes 72 initiatives by more than a dozen federal agencies to tackle competition issues across the economy, including in health care, financial…
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released by the House Committee on Oversight and Reform.
The Department of Health and Human Services withdrew requests for proposals on ways individuals could import prescription drugs from other countries where they are typically cheaper and companies could “reimport” insulin to sell at a lower price.
As patients and politicians continue searching for remedies to soaring insulin prices for diabetes patients, Walmart recently launched the first private-label version of the drug at less than half the price of brand-name versions.